Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Technology known as VAAST) include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| VXRT | Vaxart, Inc. | 2025-10-16 14:59:56 | 0.36 | 0.02 | 5.85 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VXRT | 0000072444 | Vaxart, Inc. | US92243A2006 | — | 591212264 | OTC | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 170 HARBOR WAY, SUITE 300 | SOUTH SAN FRANCISCO | CA | 94080 | UNITED STATES | US | (650) 550-3500 | 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080 | 170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080 | Aviragen Therapeutics, Inc. | Biotechnology | 2004 | Steven Lo | 109 | http://vaxart.com | 150,839,206 | 229,417,137 | 228,919,064 | Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Technology known as VAAST) include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc. | 2025-10-10 23:03:13 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 150,839,206 | 40,520,964 | 36.731 | 227,949,245 | 54,087,561 | 31.1095 |
| 2023 | 110,318,242 | -283,255,880 | -71.9701 | 173,861,684 | 38,300,035 | 28.2529 |
| 2022 | 393,574,122 | -519,574,703 | -56.8992 | 135,561,649 | 9,751,256 | 7.7508 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James Cummings, M.D. | Chief Medical Officer | 2024 | 488,087 | — | 104,400 | 179,700 | 12,156 | 1,212,535 |
| Steven Lo | Chief Executive Officer, President | 2024 | 473,810 | — | 290,000 | 272,000 | 5,588 | 2,085,768 |
| Michael J. Finney | Chief Executive Officer | 2024 | 110,521 | — | 12,312 | 46,364 | 70,124 | 305,390 |
| Andrei Floroiu | Chief Executive Officer, President | 2024 | 81,403 | — | 76,700 | 0 | 745,351 | 1,931,356 |
| Sean Tucker, Ph.D. | Chief Scientific Officer | 2024 | 446,267 | — | 104,400 | 164,300 | 11,872 | 1,155,031 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 105 |
| 2023 | 109 |
| 2022 | 164 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 28,700,000 | 7,379,000 | 107,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 74,213,000 | 68,142,000 | 81,054,000 |
| General And Administrative Expenses | 20,780,000 | 22,584,000 | 29,386,000 |
| Operating Expenses | 94,993,000 | 90,726,000 | 114,694,000 |
| Operating Income | -66,293,000 | -83,347,000 | -114,587,000 |
| Net Income | -66,948,000 | -82,465,000 | -107,758,000 |
| Earnings Per Share Basic | -0.33 | -0.57 | -0.84 |
| Earnings Per Share Diluted | — | — | — |
| Weighted Average Shares Outstanding Basic | 202,137,531 | 144,819,781 | 127,683,813 |
| Weighted Average Shares Outstanding Diluted | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 25,229,000 | 34,755,000 | 44,013,000 |
| Marketable Securities Current | 26,494,000 | 4,958,000 | 49,704,000 |
| Accounts Receivable | 5,700,000 | 3,008,000 | 20,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 318,000 | — | — |
| Total Assets Current | 68,260,000 | 45,536,000 | 99,451,000 |
| Marketable Securities Non Current | — | — | 0 |
| Property Plant And Equipment | 8,705,000 | 11,731,000 | 15,585,000 |
| Other Assets Non Current | 839,000 | 926,000 | 3,568,000 |
| Total Assets Non Current | 98,129,000 | 46,294,000 | 54,396,000 |
| Total Assets | 166,389,000 | 91,830,000 | 153,847,000 |
| Accounts Payable | 6,963,000 | 1,584,000 | 5,514,000 |
| Deferred Revenue | 65,400,000 | 0 | 2,000,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 11,378,000 | 5,634,000 | 8,084,000 |
| Total Liabilities Current | 90,878,000 | 13,724,000 | 17,921,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 439,000 | 293,000 | 231,000 |
| Total Liabilities Non Current | 16,586,000 | 20,301,000 | 25,329,000 |
| Total Liabilities | 107,464,000 | 34,025,000 | 43,250,000 |
| Common Stock | 23,000 | 15,000 | 13,000 |
| Retained Earnings | -476,522,000 | -409,574,000 | -327,109,000 |
| Accumulated Other Comprehensive Income | 4,000 | -1,000 | -299,000 |
| Total Shareholders Equity | 58,925,000 | 57,805,000 | 110,597,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 8,850,000 | 8,624,000 | 5,805,000 |
| Share Based Compensation Expense | 11,501,000 | 14,132,000 | 13,587,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 2,753,000 | 2,988,000 | -51,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 5,273,000 | -2,444,000 | 357,000 |
| Change In Other Liabilities | — | -6,979,000 | -3,323,000 |
| Cash From Operating Activities | -44,764,000 | -70,453,000 | -94,779,000 |
| Purchases Of Marketable Securities | 64,270,000 | 27,497,000 | 55,014,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 554,000 | 1,871,000 | 9,601,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -21,324,000 | 43,952,000 | -20,415,000 |
| Tax Withholding For Share Based Compensation | 214,000 | 366,000 | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 312,000 | 562,000 | 17,237,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 56,562,000 | 15,243,000 | 17,462,000 |
| Change In Cash | -9,526,000 | -11,258,000 | -97,732,000 |
| Cash At End Of Period | 25,229,000 | 34,755,000 | 44,013,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.33 | -0.57 | -0.84 |
| Price To Earnings Ratio | -2.0064 | -1.0049 | -1.1439 |
| Earnings Growth Rate | -42.1053 | -32.1429 | — |
| Price Earnings To Growth Ratio | 0.0477 | 0.0313 | — |
| Book Value Per Share | 0.2915 | 0.3992 | 0.8662 |
| Price To Book Ratio | 2.2713 | 1.435 | 1.1094 |
| Ebitda | -58,098,000 | -73,841,000 | -101,953,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 5,824,000 | 4,770,000 | 14,789,000 |
| Free Cash Flow | -50,588,000 | -75,223,000 | -109,568,000 |
| Return On Equity | -1.1362 | -1.4266 | -0.9743 |
| One Year Beta | 1.4359 | 1.8256 | 2.3157 |
| Three Year Beta | 2.072 | 2.0146 | 0.4521 |
| Five Year Beta | 0.6197 | 0.5604 | 0.4456 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Lee Phillip E | Chief Financial Officer | 2033-03-17 | 410,000 | A | 410,000 |
| Finney Kevin | Director | 2025-08-15 | 50,000 | A | 154,771 |
| Finney Kevin | Director | 2025-08-15 | 50,000 | A | 204,771 |
| Finney Kevin | Director | 2025-07-30 | 25,874 | A | 104,771 |
| Watson W. Mark | Director | 2025-07-29 | 10,000 | A | 104,125 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Custos Family Office, LLC | 2025-09-30 | 18,243 | 50,000 | 0.3649 |
| HBK Sorce Advisory LLC | 2025-09-30 | 26,216 | 75,118 | 0.349 |
| Farther Finance Advisors, LLC | 2025-09-30 | 10 | 27 | 0.3704 |
| LVM CAPITAL MANAGEMENT LTD/MI | 2025-09-30 | 9,000 | 25,000 | 0.36 |
| Corient Private Wealth LLC | 2025-06-30 | 8,961 | 19,825 | 0.452 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD VALLEY FORGE FUNDS | 2025-06-30 | INSTITUTIONAL SHARES | VBAIX | 148,173 | 66,974.2 | 0.0001 |
| VANGUARD VALLEY FORGE FUNDS | 2025-06-30 | ADMIRAL SHARES | VBIAX | 148,173 | 66,974.2 | 0.0001 |
| VANGUARD VALLEY FORGE FUNDS | 2025-06-30 | INVESTOR SHARES | VBINX | 148,173 | 66,974.2 | 0.0001 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Select Shares | VSEMX | 3,100,232 | 1,401,304.86 | 0.0012 |
| VANGUARD INDEX FUNDS | 2025-06-30 | Institutional Plus Shares | VEMPX | 3,100,232 | 1,401,304.86 | 0.0012 |